Gllbenclamide 5mg, Mettorrmin Hydrochloride 500mg + Piogltazone Hydrochloride 15mg Tablet (ilm coated)

Gllbenclamide 5mg, Mettorrmin Hydrochloride 500mg + Piogltazone Hydrochloride 15mg Tablet (ilm coated) is a tablet formulated with Gllbenclamide 5mg, Mettorrmin Hydrochloride 500mg + Piogltazone Hydrochloride 15mg (ilm coated). The listed active ingredient profile is Gllbenclamide; Mettorrmin Hydrochloride; Piogltazone Hydrochloride, placing the product in the oral antidiabetic category. The formulation contains one or more oral glucose-lowering medicines used in clinician-directed management of type 2 diabetes mellitus. The source identifies the dosage form as tablet with not specified presentation. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.